CeramiSphere

  • Technology utilizes combination of emulsion chemistry and sol-gel chemistry to create silicon dioxide micro- and nanoparticles for encapsulation of actives at room temperature
  • Pursuing applications with partners in aircraft anti-corrosion, animal and human healthcare, security, and auto...

This item has been archived in line with our efforts to keep our content relevant and up to date for our readership. For further assistance, please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

Pear Therapeutics CEO claims Novartis trial of schizophrenia therapeutic was flawed; tensions grow between digital therapeutics and pharma

News Commentary | April 16, 2021

The CEO of Pear Therapeutics is claiming that trial irregularities are causing misleading results regarding the schizophrenia product rolled out last year. While the results of this study are unlikely to change anything for Pear Therapeutics directly, the claimed lack of rigor in the trial speaks to... Not part of subscription

Genevant enters partnership with Takeda for developing rare liver disease therapies

News Commentary | September 08, 2021

Genevant Sciences develops lipid nanoparticle (LNP) nucleic acid delivery techniques, which can be utilized for mRNA‑based applications including vaccines, protein production, and nonviral gene therapies. The two companies reached an agreement for Genevant to develop therapeutics for two undisclosed... Not part of subscription

Regulus Therapeutics

Company Profile | December 01, 2021

Regulus Therapeutics was created as a joint venture between Alnylam Pharmaceuticals, an RNAi therapeutics company, and Isis Pharmaceuticals (now known as Ionis Pharmaceuticals), a company focused on anti‑sense technologies and therapeutics, in 2007 Regulus Therapeutics is focused on the ... Not part of subscription